Rescue therapy with upadacitinib in severe Crohn’s disease
Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, Poland
Article file
- Clinton J, Motwani KK, Schwartz S, et al. Upadacitinib as rescue therapy for the treatment of acute severe colitis in an acute care setting. Dig Dis Sci 2024; 69: 1105-9. Rydzewska G, Eder P, Gonciarz M, et al. A proposed comprehensive model of care for inflammatory bowel disease in Poland. Gastroenterology Rev 2025; 20: 142-7. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 2018; 113: 481-517. Gade AK, Douthit NT, Townsley E. Medical management of Crohn’s disease. Cureus 2020; 12: e8351. Łodyga M, Eder P, Gawron-Kiszka M, et al. Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Gastroenterology Rev 2021; 16: 257-96. Patel AV, Moore J, Sultan K. Infliximab as rescue therapy for hospitalized patients with Crohn’s disease failing intravenous corticosteroids. Am J Ther 2022; 29: e611-5. Whitlock AE, Arndt KR, Zakopoulos I, et al. Safety and efficacy of inpatient infliximab rescue therapy for acute Crohn’s disease flares. Am Surg 2024; 90: 1591-8. Sinagra E, Orlando A, Mocciaro F, et al. Clinical course of severe colitis: a comparison between Crohn’s disease and ulcerative colitis. J Biol Regul Homeost Agents 2018; 32: 415-23. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45. Lee JS, Tato CM, Joyce-Shaikh B, et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity 2015; 43: 727-38. Ogawa A, Andoh A, Araki Y, et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 2004; 110: 55-62. Fauny M, Moulin D, D’Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis 2020; 79: 1132-38. Grümme L, Dombret S, Knösel T, et al. Colitis induced by IL-17A-inhibitors. Clin J Gastroenterol 2024; 17: 263-70. Ju J, Dai Y, Yang J, et al. Crohn’s disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report. BMC Gastroenterol 2020; 20: 340. Mohamed MF, Bhatnagar S, Parmentier JM, et al. Upadacitinib: mechanism of action, clinical, and translational science. Clin Transl Sci 2024; 17: e13688. Loftus EV Jr, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med 2023; 388: 1966-80. Mohamed MF, Klünder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet 2020; 59: 531-44. Friedberg S, Choi D, Hunold T, et al. Upadacitinib is effective and safe in both ulcerative colitis and Crohn’s disease: prospective real-world experience. Clin Gastroenterol Hepatol 2023; 21: 1913-23.e2.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
